Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia

PD-1/PD-L1 inhibitors such as pembrolizumab have radically improved the prognosis for many patients with advanced malignancies. Although revolutionary, its use can be complicated and limited by various immune-related adverse effects. Effective management depends on early recognition and prompt inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Oommen, Tiffany T., Sun, Kelly, Barranco-Trabi, Javier, Berenberg, Jeffrey, Kim, Myungjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839403/
https://www.ncbi.nlm.nih.gov/pubmed/36644340
http://dx.doi.org/10.1155/2023/9160326
_version_ 1784869476685053952
author Oommen, Tiffany T.
Sun, Kelly
Barranco-Trabi, Javier
Berenberg, Jeffrey
Kim, Myungjin
author_facet Oommen, Tiffany T.
Sun, Kelly
Barranco-Trabi, Javier
Berenberg, Jeffrey
Kim, Myungjin
author_sort Oommen, Tiffany T.
collection PubMed
description PD-1/PD-L1 inhibitors such as pembrolizumab have radically improved the prognosis for many patients with advanced malignancies. Although revolutionary, its use can be complicated and limited by various immune-related adverse effects. Effective management depends on early recognition and prompt intervention. Herein, we describe a unique syndrome of hypercalcemia, with associated acute renal injury and hypoxic respiratory failure that was responsive to corticosteroids suggestive of immunotoxicity from pembrolizumab.
format Online
Article
Text
id pubmed-9839403
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-98394032023-01-14 Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia Oommen, Tiffany T. Sun, Kelly Barranco-Trabi, Javier Berenberg, Jeffrey Kim, Myungjin Case Rep Nephrol Case Report PD-1/PD-L1 inhibitors such as pembrolizumab have radically improved the prognosis for many patients with advanced malignancies. Although revolutionary, its use can be complicated and limited by various immune-related adverse effects. Effective management depends on early recognition and prompt intervention. Herein, we describe a unique syndrome of hypercalcemia, with associated acute renal injury and hypoxic respiratory failure that was responsive to corticosteroids suggestive of immunotoxicity from pembrolizumab. Hindawi 2023-01-06 /pmc/articles/PMC9839403/ /pubmed/36644340 http://dx.doi.org/10.1155/2023/9160326 Text en Copyright © 2023 Tiffany T. Oommen et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Oommen, Tiffany T.
Sun, Kelly
Barranco-Trabi, Javier
Berenberg, Jeffrey
Kim, Myungjin
Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia
title Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia
title_full Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia
title_fullStr Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia
title_full_unstemmed Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia
title_short Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia
title_sort pembrolizumab induced calcitriol-mediated hypercalcemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839403/
https://www.ncbi.nlm.nih.gov/pubmed/36644340
http://dx.doi.org/10.1155/2023/9160326
work_keys_str_mv AT oommentiffanyt pembrolizumabinducedcalcitriolmediatedhypercalcemia
AT sunkelly pembrolizumabinducedcalcitriolmediatedhypercalcemia
AT barrancotrabijavier pembrolizumabinducedcalcitriolmediatedhypercalcemia
AT berenbergjeffrey pembrolizumabinducedcalcitriolmediatedhypercalcemia
AT kimmyungjin pembrolizumabinducedcalcitriolmediatedhypercalcemia

Ejemplares similares